NOTCH signaling was reported to be altered in approximately one third of NSCLCs (14).Numerous studies have also suggested that activation of NOTCH correlates with poor clinicaloutcomes in NSCLC patients without TP53 mutations and it is a biomarker forpredicting survival time in patients with NSCLC (15). This evidence concerns the gene TP53 and non-small cell lung carcinoma.